Cellares, an Integrated Development and Manufacturing Organization, announced the selection of Cytek Biosciences as one of five best-in-class technology providers for its Cell Q platform. The Cell Q is the first fully automated quality control testing platform purpose-built to match commercial-scale throughput for cell therapy manufacturing. This partnership integrates Cytek's technology into a critical solution for the cell therapy industry.
The Cell Q system is designed to automate and streamline labor-intensive, error-prone in-process and release assays, supporting automated QC release testing of up to 6,000 cell therapy batches per year. Cytek Biosciences' contribution, alongside other leading technology providers, enhances Cell Q's capabilities in flow cytometry. This collaboration aims to reduce costs and operational burdens compared to traditional manual methods.
This strategic partnership expands Cytek's reach into the commercial-scale cell therapy quality control market, a high-growth area. The integration of Cytek's technology into Cell Q streamlines critical QC testing operations, from high-throughput sample preparation to real-time data tracking and reporting. This move positions Cytek as a key enabler for advanced cell therapy manufacturing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.